// Auto-generated - do not edit
export const substanceName = "Citicoline";
export const sources = [{"id":"drugbank","fileName":"DRUGBANK - Citicoline.md","displayName":"DrugBank","size":14428},{"id":"isomerdesign","fileName":"ISOMERDESIGN - Citicoline.md","displayName":"Isomer Design","size":915},{"id":"protestkit","fileName":"PROTESTKIT - Citicoline.json","displayName":"Protest Kit","size":2285},{"id":"psychonautwiki","fileName":"PSYCHONAUTWIKI - Citicoline.md","displayName":"PsychonautWiki","size":19511},{"id":"wikipedia","fileName":"WIKIPEDIA - Citicoline.md","displayName":"Wikipedia","size":6050}];
export const contents: Record<string, string> = {
  "drugbank": `# Citicoline
*Source: https://go.drugbank.com/drugs/DB12153*

## Overview

### Description

This compound belongs to the class of organic compounds known as pyrimidine ribonucleoside diphosphates. These are pyrimidine ribonucleotides with diphosphate group  linked to the ribose moiety.

### Background

Citicoline is a donor of choline in biosynthesis of choline-containing phosphoglycerides. It has been investigated for the treatment, supportive care, and diagnosis of Mania, Stroke, Hypomania, Cocaine Abuse, and Bipolar Disorder, among others.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available

## Chemical Information

**Synonyms:** CDP-choline
CDP-colina
citicolina
Citicoline
citidin difosfato de colina
Cytidine 5'-(choline diphosphate)
Cytidine 5'-(cholinyl pyrophosphate)
Cytidine 5'-diphosphocholine
Cytidine 5'-diphosphoric choline
Cytidine-5'-diphosphocholine

**Chemical Formula:** C
14
H
26
N
4
O
11
P
2

**SMILES:** C[N+](C)(C)CCOP([O-])(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(N)=NC1=O

**Weight:** Average: 488.324
Monoisotopic: 488.107330718

**IUPAC Name:** {2-[({[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphono)oxy]ethyl}trimethylazanium

## Additional Information

### Summary

Citicoline
is an endogenous intermediate in the formation of phosphatidylcholine from choline which is thought to have neuroprotective effects.

### Generic Name

Citicoline

### DrugBank Accession Number

DB12153

### Modality

Small Molecule

### Groups

Approved, Investigational, Withdrawn

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Citicoline (DB12153)
×
Close

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Management of
Degenerative brain disorder
••••••••••••
Create Account
Management of
Parkinsonian syndromes
••••••••••••
Create Account
•••••••••• •••••••••• ••••••••
Create Account

### Mechanism of action

Target
Actions
Organism
U
LicC protein
Not Available
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)

### Product Ingredients

Ingredient
UNII
CAS
InChI Key
Citicoline sodium
7XQ5AKD9YD
33818-15-4
YWAFNFGRBBBSPD-OCMLZEEQSA-M

### ATC Codes

N06BX06 — Citicoline
N06BX — Other psychostimulants and nootropics
N06B — PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06 — PSYCHOANALEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Amines
Central Nervous System Agents
Cytidine Diphosphate
Cytosine Nucleotides
Nervous System
Nootropic Agents
Nucleic Acids, Nucleotides, and Nucleosides
Nucleotides
Onium Compounds
Psychoanaleptics
Psychostimulants, Agents Used for ADHD and Nootropics
Pyrimidine Nucleotides
Pyrimidines
Quaternary Ammonium Compounds
Ribonucleotides
Trimethyl Ammonium Compounds

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as pyrimidine ribonucleoside diphosphates. These are pyrimidine ribonucleotides with diphosphate group  linked to the ribose moiety.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Pyrimidine nucleotides
Sub Class
Pyrimidine ribonucleotides
Direct Parent
Pyrimidine ribonucleoside diphosphates
Alternative Parents
Pentose phosphates
/
Glycosylamines
/
Phosphocholines
/
Monosaccharide phosphates
/
Organic pyrophosphates
/
Pyrimidones
/
Aminopyrimidines and derivatives
/
Monoalkyl phosphates
/
Hydropyrimidines
/
Imidolactams
/
Tetraalkylammonium salts
/
Tetrahydrofurans
/
Heteroaromatic compounds
/
Secondary alcohols
/
1,2-diols
/
Oxacyclic compounds
/
Azacyclic compounds
/
Organic salts
/
Organic zwitterions
/
Hydrocarbon derivatives
/
Organopnictogen compounds
/
Organic oxides
/
Primary amines
show 13 more
Substituents
1,2-diol
/
Alcohol
/
Alkyl phosphate
/
Amine
/
Aminopyrimidine
/
Aromatic heteromonocyclic compound
/
Azacycle
/
Glycosyl compound
/
Heteroaromatic compound
/
Hydrocarbon derivative
/
Hydropyrimidine
/
Imidolactam
/
Monoalkyl phosphate
/
Monosaccharide
/
Monosaccharide phosphate
/
N-glycosyl compound
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organic phosphoric acid derivative
/
Organic pyrophosphate
/
Organic salt
/
Organic zwitterion
/
Organoheterocyclic compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Oxacycle
/
Pentose monosaccharide
/
Pentose phosphate
/
Pentose-5-phosphate
/
Phosphocholine
/
Phosphoric acid ester
/
Primary amine
/
Pyrimidine
/
Pyrimidine ribonucleoside diphosphate
/
Pyrimidone
/
Quaternary ammonium salt
/
Secondary alcohol
/
Tetraalkylammonium salt
/
Tetrahydrofuran
show 31 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
phosphocholines, nucleotide-(amino alcohol)s (
CHEBI:16436
)

### Kingdom

Organic compounds

### Super Class

Nucleosides, nucleotides, and analogues

### Class

Pyrimidine nucleotides

### Sub Class

Pyrimidine ribonucleotides

### Direct Parent

Pyrimidine ribonucleoside diphosphates

### Alternative Parents

Pentose phosphates
/
Glycosylamines
/
Phosphocholines
/
Monosaccharide phosphates
/
Organic pyrophosphates
/
Pyrimidones
/
Aminopyrimidines and derivatives
/
Monoalkyl phosphates
/
Hydropyrimidines
/
Imidolactams
/
Tetraalkylammonium salts
/
Tetrahydrofurans
/
Heteroaromatic compounds
/
Secondary alcohols
/
1,2-diols
/
Oxacyclic compounds
/
Azacyclic compounds
/
Organic salts
/
Organic zwitterions
/
Hydrocarbon derivatives
/
Organopnictogen compounds
/
Organic oxides
/
Primary amines
show 13 more

### Substituents

1,2-diol
/
Alcohol
/
Alkyl phosphate
/
Amine
/
Aminopyrimidine
/
Aromatic heteromonocyclic compound
/
Azacycle
/
Glycosyl compound
/
Heteroaromatic compound
/
Hydrocarbon derivative
/
Hydropyrimidine
/
Imidolactam
/
Monoalkyl phosphate
/
Monosaccharide
/
Monosaccharide phosphate
/
N-glycosyl compound
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organic phosphoric acid derivative
/
Organic pyrophosphate
/
Organic salt
/
Organic zwitterion
/
Organoheterocyclic compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Oxacycle
/
Pentose monosaccharide
/
Pentose phosphate
/
Pentose-5-phosphate
/
Phosphocholine
/
Phosphoric acid ester
/
Primary amine
/
Pyrimidine
/
Pyrimidine ribonucleoside diphosphate
/
Pyrimidone
/
Quaternary ammonium salt
/
Secondary alcohol
/
Tetraalkylammonium salt
/
Tetrahydrofuran
show 31 more

### Molecular Framework

Aromatic heteromonocyclic compounds

### External Descriptors

phosphocholines, nucleotide-(amino alcohol)s (
CHEBI:16436
)

### UNII

536BQ2JVC7

### CAS number

987-78-0

### InChI Key

RZZPDXZPRHQOCG-OJAKKHQRSA-N

### InChI

InChI=1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/t9-,11-,12-,13-/m1/s1

### General References

AIFA Product Information: Difosfocin (citicoline) solution for injection [
Link
]
INVIMA Product Information: Complegel NF (citicoline) coated tablets [
Link
]

### External Links

Human Metabolome Database
HMDB0001413
KEGG Drug
D00057
KEGG Compound
C00307
PubChem Substance
347911290
ChemSpider
13207
RxNav
997602
ChEBI
16436
ChEMBL
CHEMBL1231700
PDBe Ligand
CDC
Wikipedia
Citicoline

### Human Metabolome Database

HMDB0001413

### KEGG Drug

D00057

### KEGG Compound

C00307

### PubChem Substance

347911290

### ChemSpider

13207

### RxNav

997602

### ChEBI

16436

### ChEMBL

CHEMBL1231700

### PDBe Ligand

CDC

### Wikipedia

Citicoline

### PDB Entries

1jyl
/
3hl4
/
4bet
/
4mvc
/
4mvd
/
4zcs
/
8erp
/
8gyw
/
8urp

### Dosage Forms

Form
Route
Strength
Injection, solution
Parenteral
500 MG/3ML
Injection
Intramuscular; Intravenous
1000 mg/4ml
Injection
Intramuscular; Intravenous
500 mg/4ml
Injection, solution
Intramuscular; Intravenous
1045 MG
Injection, solution
Intramuscular; Intravenous
522.5 MG
Tablet
Oral
522.500 mg
Injection, solution
Parenteral
1 G/5ML
Injection
Intramuscular; Intravenous
130.63 mg
Injection, solution
Parenteral
1000 MG/5ML
Injection, solution
Intramuscular; Intravenous
0.1 g/2ml
Injection, solution
Intramuscular; Intravenous
1 g/4ml
Injection, solution
Intramuscular; Intravenous
250 mg/2ml
Injection, solution
Intramuscular; Intravenous
500 mg/4ml
Injection, solution
Intramuscular; Intravenous; Intravenous drip
100 mg
Injection, solution
Intramuscular; Intravenous; Intravenous drip
1000 mg
Injection, solution
Intramuscular
Injection
Intramuscular; Intravenous
125 mg/ml
Injection, solution
Intramuscular; Intravenous
1000 mg/4ml
Solution
Oral
1 g
Injection
Intramuscular; Intravenous
125 mg
Tablet
Oral
522.6 mg
Tablet, film coated
Oral
250 mg
Injection, solution
Intramuscular; Intravenous
1000 mg
Tablet
Oral
522.506 mg
Injection
Intramuscular; Intravenous
100 mg
Injection
Intramuscular; Intravenous
1000 mg
Injection
Intramuscular; Intravenous
250 mg
Injection
Intramuscular; Intravenous
500 mg
Injection
Intramuscular; Intravenous
522.537 mg
Injection
Intramuscular; Intravenous
Injection, solution
Parenteral
100 MG/2ML
Injection, solution
Parenteral
1000 MG/4ML
Injection, solution
Parenteral
250 MG/2ML
Injection, solution
Parenteral
500 MG/4ML
Injection
Intramuscular; Intravenous
250 MG/2ML
Solution
Parenteral
500.000 mg
Solution
Parenteral
1045.020 mg
Solution
Oral
1000.000 mg
Injection, solution
Parenteral
1 G/4ML
Solution
Intravenous
1000.000 mg
Tablet
Oral
500 mg
Tablet, coated
Oral
500 mg
Injection, solution
Intramuscular; Intravenous
500 mg
Tablet, coated
Oral
50000000 mg
Injection, solution
Intramuscular; Intravenous
125 mg/ml
Solution
Oral
1000 MG
Solution
Intravenous
500.000 mg
Solution
Oral
10.45 g
Solution
Intravenous
1047.155 mg
Tablet
Oral
500.000 mg
Solution
Oral
1000 mg/4ml

### Predicted Properties

Property
Value
Source
Water Solubility
7.99 mg/mL
ALOGPS
logP
-1.4
ALOGPS
logP
-7.1
Chemaxon
logS
-1.8
ALOGPS
pKa (Strongest Acidic)
1.84
Chemaxon
pKa (Strongest Basic)
-2.6
Chemaxon
Physiological Charge
-1
Chemaxon
Hydrogen Acceptor Count
10
Chemaxon
Hydrogen Donor Count
4
Chemaxon
Polar Surface Area
213.5 Å
2
Chemaxon
Rotatable Bond Count
10
Chemaxon
Refractivity
113.58 m
3
·mol
-1
Chemaxon
Polarizability
42.54 Å
3
Chemaxon
Number of Rings
2
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
No
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
-
0.9964
Blood Brain Barrier
-
0.626
Caco-2 permeable
-
0.6489
P-glycoprotein substrate
Substrate
0.6427
P-glycoprotein inhibitor I
Non-inhibitor
0.9504
P-glycoprotein inhibitor II
Non-inhibitor
0.9873
Renal organic cation transporter
Non-inhibitor
0.9328
CYP450 2C9 substrate
Non-substrate
0.7797
CYP450 2D6 substrate
Non-substrate
0.8109
CYP450 3A4 substrate
Substrate
0.6171
CYP450 1A2 substrate
Non-inhibitor
0.8289
CYP450 2C9 inhibitor
Non-inhibitor
0.8439
CYP450 2D6 inhibitor
Non-inhibitor
0.8274
CYP450 2C19 inhibitor
Non-inhibitor
0.8009
CYP450 3A4 inhibitor
Non-inhibitor
0.8877
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.9675
Ames test
Non AMES toxic
0.6538
Carcinogenicity
Non-carcinogens
0.8806
Biodegradation
Ready biodegradable
0.7564
Rat acute toxicity
1.6863 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.9031
hERG inhibition (predictor II)
Non-inhibitor
0.6674
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-00fr-7649200000-859d046834f1fbd3d535
MS/MS Spectrum - Quattro_QQQ 10V, Positive
LC-MS/MS
splash10-0006-0001900000-a9f38ff6b185b45f04b3
MS/MS Spectrum - Quattro_QQQ 25V, Positive
LC-MS/MS
splash10-03e9-0590000000-b021677d064d65810ee0
MS/MS Spectrum - Quattro_QQQ 40V, Positive
LC-MS/MS
splash10-001i-0900000000-7570bbb10dd9fa288442
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positive
LC-MS/MS
splash10-000i-0000900000-8b411373962b073b4d22
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) 30V, Positive
LC-MS/MS
splash10-000i-0001900000-6e7cc437ad79eb13c032
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positive
LC-MS/MS
splash10-01qi-1932200000-9c3803cefdd9c6285a7c
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Negative
LC-MS/MS
splash10-004i-6505900000-3d534aab6e40915c3642
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Negative
LC-MS/MS
splash10-004i-6505900000-fc13e5ad403e7faf8218
LC-MS/MS Spectrum - LC-ESI-QTOF , negative
LC-MS/MS
splash10-004i-6505900000-3d534aab6e40915c3642
LC-MS/MS Spectrum - LC-ESI-QTOF , negative
LC-MS/MS
splash10-004i-6505900000-fc13e5ad403e7faf8218
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-000i-0000900000-8b411373962b073b4d22
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-000i-0001900000-6e7cc437ad79eb13c032
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-01qi-1932200000-4a7ae92c6e127d2ce453
1H NMR Spectrum
1D NMR
Not Applicable
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable
[1H,13C] 2D NMR Spectrum
2D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
235.1178185
predicted
DarkChem Lite v0.1.0
[M-H]-
228.3908185
predicted
DarkChem Lite v0.1.0
[M-H]-
186.6222
predicted
DeepCCS 1.0 (2019)
[M+H]+
236.3929185
predicted
DarkChem Lite v0.1.0
[M+H]+
229.6900185
predicted
DarkChem Lite v0.1.0
[M+H]+
188.5176
predicted
DeepCCS 1.0 (2019)
[M+Na]+
235.3875185
predicted
DarkChem Lite v0.1.0
[M+Na]+
229.0222185
predicted
DarkChem Lite v0.1.0
[M+Na]+
194.3821
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)

### Pharmacological action

Unknown

### Specific Function

metal ion binding

### Gene Name

licC

### Uniprot ID

A0A0H2UQB5

### Uniprot Name

LicC protein

### Molecular Weight

26903.28 Da

`,
  "isomerdesign": `# Citicoline
*Source: https://isomerdesign.com/PiHKAL/explore.php?id=11372*

## Chemical Data

**IUPAC Name:** 2-{[{[{[5-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl]oxy}(hydroxy)phosphoryl]oxy}-N,N,N-trimethylethan-1-aminium

**Molecular Formula:** C14H26N4O11P2

**Molecular Weight:** 488.324

**SMILES:** \`OC1C(COP(=O)(OP(=O)(OCC[N+](C)(C)C)O)O)OC(C1O)n1ccc(nc1=O)N\`

**InChI:** \`InChI=1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/p+1\`

## External References

- [](https://en.wikipedia.org/wiki/Markush_structure)
- [285](https://www.chemspider.com/Chemical-Structure.285.html/)
- [291](https://pubchem.ncbi.nlm.nih.gov/compound/291)
- [Q126615061](https://www.wikidata.org/wiki/Q126615061)
- [Citicoline](https://en.wikipedia.org/wiki/Citicoline)
`,
  "protestkit": `{
  "url": "https://psychonautwiki.org/wiki/Citicoline",
  "experiencesUrl": "https://www.reddit.com/search/?q=Citicoline",
  "name": "Citicoline",
  "aliases": [],
  "aliasesStr": "",
  "summary": null,
  "reagents": null,
  "classes": {
    "chemical": [
      "Ammonium salt"
    ],
    "psychoactive": [
      "Nootropic"
    ]
  },
  "toxicity": [
    "extremely low toxicity"
  ],
  "addictionPotential": "not habit-forming",
  "tolerance": null,
  "crossTolerances": null,
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Threshold",
          "value": "50 mg"
        },
        {
          "name": "Light",
          "value": "100 - 250 mg"
        },
        {
          "name": "Common",
          "value": "250 - 1000 mg"
        },
        {
          "name": "Strong",
          "value": "1000 - 2000 mg"
        },
        {
          "name": "Heavy",
          "value": "2000 mg +"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "1.0 - 2.0 hours"
        },
        {
          "name": "Come up",
          "value": "2.0 - 3.0 hours"
        },
        {
          "name": "Peak",
          "value": "2.5 - 3.5 hours"
        },
        {
          "name": "Offset",
          "value": "30.0 - 40.0 hours"
        },
        {
          "name": "Total",
          "value": "58.0 - 74.0 hours"
        },
        {
          "name": "After effects",
          "value": "40.0 - 60.0 hours"
        }
      ],
      "bioavailability": "98%"
    }
  ],
  "interactions": null,
  "effects": "Memory enhancement, Headache, Dream potentiation, Mindfulness, Stimulation, Wakefulness, Appetite suppression, Pain relief, Visual acuity enhancement, Addiction suppression, Body odor alteration, Focus intensification",
  "categorized_effects": {
    "Physical effects": [
      "Headache",
      "Stimulation",
      "Appetite suppression",
      "Pain relief",
      "Body odor alteration"
    ],
    "Mental effects": [
      "Memory enhancement",
      "Dream potentiation",
      "Mindfulness",
      "Wakefulness",
      "Focus intensification"
    ],
    "Sensory effects": [
      "Visual acuity enhancement"
    ],
    "Uncategorized effects": [
      "Addiction suppression"
    ]
  }
}`,
  "psychonautwiki": `# Citicoline
*Source: https://psychonautwiki.org/wiki/Citicoline*

## Dosage & Duration

### Oral

**Dosage:**
- Bioavailability: 98%
- Threshold: 50 mg
- Light: 100 - 250 mg
- Common: 250 - 1000 mg
- Strong: 1000 - 2000 mg
- Heavy: 2000 mg +

**Duration:**
- Total: 58 - 74 hours
- Onset: 1 - 2 hours
- Come up: 2 - 3 hours
- Peak: 2.5 - 3.5 hours
- Offset: 30 - 40 hours
- After effects: 40 - 60 hours

**Citicoline** ( **CDP-choline** , **cytidine 5'-diphosphocholine** ) is a water soluble nutrient which serves as a precursor to both [choline](https://psychonautwiki.org/wiki/Choline) and cytidine within the brain (which later converts to [uridine](/w/index.php?title=Uridine&action=edit&redlink=1) ). To humans, choline is an essential nutrient as its role in reducing the risk of neural tube defects, fatty liver disease, and other pathologies have been documented. CDP-choline is one of the three choline-containing phospholipids that can be orally supplemented (the other two being [alpha-GPC](https://psychonautwiki.org/wiki/Alpha-GPC) and phosphatidylcholine).

This supplement is catered towards preventing or treating memory impairments associated with aging because both of the molecules it confers are neuroprotective and potentially enhance learning. This effect may also benefit younger populations as well. It appears to be more efficient than phosphatidylcholine (PC) itself in this role, in part due to also increasing PC synthesis in the brain.

Citicoline has also been implicated in the treatments of cognitive impairments, caused by stroke, vascular dementia, Alzheimer’s disease, Parkinson’s disease, and more.

The potency of this compound is somewhat comparable to that of [alpha-GPC](https://psychonautwiki.org/wiki/Alpha-GPC) . One study has noted an increase in attention with low dose CDP-choline (which needs to be replicated), and CDP-choline may have roles as an anti-addictive compound against both cocaine and (preliminary evidence suggests) food as well.

When taken as a supplement, this compound has [nootropic](https://psychonautwiki.org/wiki/Nootropic) effects. It is readily available and commonly sold for this purpose through the use of online supplement vendors.

## Chemistry

Citicoline, or cytidine diphosphate-choline, is a naturally occurring substance found in human cell tissue and synthesized as a sodium salt as a supplement. Its chemical structure is comprised of a cytidine nucleoside attached to a choline group through a diphosphate bridge. Citicoline is a chemical intermediary in the biosynthesis of phosphatidylcholine, a major phospholipid in cell membranes.

The choline subcomponent of citicoline is comprised of a trimethyl ammonium salt with an additional ethanol group attached. In citicoline, the terminal alcohol group is incorporated into the phosphate bridge connecting the choline sub-group to cytidine. Cytidine is a nucleoside made of cytosine bonded to a ribose ring.

## Pharmacology

CDP-choline breaks down into two key components, [choline](https://psychonautwiki.org/wiki/Choline) and cytidine. Choline and its metabolites are needed for three main physiological purposes: structural integrity and signaling roles for cell membranes as well as cholinergic neurotransmission ( [acetylcholine](https://psychonautwiki.org/wiki/Acetylcholine) synthesis). This process essentially allows acetylcholine to accumulate at higher levels than that which it otherwise would. As acetylcholine is involved in the function of memory, this could potentially account for its [nootropic](https://psychonautwiki.org/wiki/Nootropic) effects.

Cytidine is the second metabolite which is a critical step in the synthesis of [uridine](/w/index.php?title=Uridine&action=edit&redlink=1) , which increases the efficiency of phosphatidylcholine. Uridine supplementation also appears to enhance [dopamine](https://psychonautwiki.org/wiki/Dopamine) output from activated [neurons](https://psychonautwiki.org/wiki/Neuron) without significantly affecting basal levels of dopamine. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*] This could account for its improvements in spatial short-term memory, recognition, recall, attention, and executive functions after prolonged supplementation. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]

## Subjective effects

***Disclaimer:** The effects listed below cite the [Subjective Effect Index](https://psychonautwiki.org/wiki/Subjective_effect_index) ( **SEI** ), an open research literature based on anecdotal user reports and the personal analyses of [PsychonautWiki](https://psychonautwiki.org/wiki/PsychonautWiki) [contributors](https://psychonautwiki.org/wiki/Special:TopUsers) . As a result, they should be viewed with a healthy degree of skepticism.*

*It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. *Likewise, **adverse effects** become increasingly likely with higher doses and may include **addiction, severe injury, or death*** ☠.*
### Physical effects
 
- - **[Appetite suppression](https://psychonautwiki.org/wiki/Appetite_suppression)**
- **[Stimulation](https://psychonautwiki.org/wiki/Stimulation)** - The stimulation which citicoline presents can be considered as primarily subtle and less than that of [caffeine](https://psychonautwiki.org/wiki/Caffeine) .
- **[Headaches](https://psychonautwiki.org/wiki/Headaches)**
- **[Pain relief](https://psychonautwiki.org/wiki/Pain_relief)** - CDP-choline appears to have painkilling effects via the nicotinic acetylcholine receptors in a dosage-dependent manner.
- **[Body odor alteration](https://psychonautwiki.org/wiki/Body_odor_alteration)** - This may occur in some populations, especially those suffering from trimethylaminuria. [Choline](https://psychonautwiki.org/wiki/Choline) (a byproduct of CDP-choline) is a precursor to trimethylamine, which some people are not able to break down easily, often resulting in a fishy smell.
- **[Acuity enhancement](https://psychonautwiki.org/wiki/Acuity_enhancement)** - Citicoline may prevent and treat eye damage related to glaucoma. ### Cognitive effects
 
- - **[Wakefulness](https://psychonautwiki.org/wiki/Wakefulness)** - In comparison to [Alpha-GPC](https://psychonautwiki.org/wiki/Alpha-GPC) , Citicoline manifests itself primarily in a mentally stimulating manner over a physical stimulation.
- **[Dream potentiation](https://psychonautwiki.org/wiki/Dream_potentiation)**
- **[Focus enhancement](https://psychonautwiki.org/wiki/Focus_enhancement)**
- **[Addiction suppression](https://psychonautwiki.org/wiki/Addiction_suppression)** - Citicoline has been shown to reduce psychological cravings in cocaine-dependent populations who actively seek substance abuse treatment.
- **[Mindfulness](https://psychonautwiki.org/wiki/Mindfulness)**
- **[Memory enhancement](https://psychonautwiki.org/wiki/Memory_enhancement)**
### Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our [experience index](https://psychonautwiki.org/wiki/Experience_index) . Additional experience reports can be found here:

- [Erowid Experience Vaults: Citicoline](https://www.erowid.org/experiences/subs/exp_Citicoline.shtml)

## Toxicity and harm potential

Citicoline is non-addictive, is not known to cause brain damage, and has an extremely low toxicity relative to dose. Similar to many other [nootropics](https://psychonautwiki.org/wiki/Nootropics) substances, there are relatively few physical side effects associated with acute citicoline exposure. Various studies have shown that in reasonable doses in a careful context, it presents no negative cognitive, psychiatric or toxic physical consequences of any sort.

It is strongly recommended that one use [harm reduction practices](https://psychonautwiki.org/wiki/Responsible_drug_use) when using this substance.

### Tolerance and addiction potential

Citicoline is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Citicoline does not seem to build up an immediate tolerance and becomes stronger with prolonged use due to its long half-life. It is not recommended to take citicoline for extended periods longer than two weeks.

### Dangerous interactions

Citicoline is a suspected monoaminergic substance. Citicoline and [MAOIs](https://psychonautwiki.org/wiki/MAOIs) are a potentially dangerous combination. It is likely that MAOIs could increase the effects of Alpha-GPC unpredictably. Taking this chemical while on prescription MAOIs is strongly discouraged.

## Legal status

## Literature

- Mcglade, E., Locatelli, A., Hardy, J., Kamiya, T., Morita, M., Morishita, K., … Yurgelun-Todd, D. (2012). Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women. Food and Nutrition Sciences, 336103(June), 769–773. [https://doi.org/10.4236/fns.2012.36103](https://doi.org/10.4236/fns.2012.36103)
- Parisi, V., Coppola, G., Centofanti, M., Oddone, F., Maria Angrisani, A., Ziccardi, L., … Manni, G. (2008). Evidence of the neuroprotective role of citicoline in glaucoma patients. Progress in Brain Research, 173(8), 541–554. [https://doi.org/10.1016/S0079-6123(08)01137-0](https://doi.org/10.1016/S0079-6123(08)01137-0)
- Bagdas, D., Sonat, F. A., Hamurtekin, E., Sonal, S., & Gurun, M. S. (2011). The antihyperalgesic effect of cytidine-5’-diphosphate-choline in neuropathic and inflammatory pain models. Behavioural Pharmacology, 22(5–6), 589–598. [https://doi.org/10.1097/FBP.0b013e32834a1efb](https://doi.org/10.1097/FBP.0b013e32834a1efb)
- Hamurtekin, E., & Sibel Gurun, M. (2006). The antinociceptive effects of centrally administered CDP-choline on acute pain models in rats: The involvement of cholinergic system. Brain Research, 1117(1), 92–100. [https://doi.org/10.1016/j.brainres.2006.07.118](https://doi.org/10.1016/j.brainres.2006.07.118)
- Killgore, W. D. S., Ross, A. J., Kamiya, T., Kawada, Y., Renshaw, P. F., & Yurgelun-Todd, D. A. (2010). Citicoline affects appetite and cortico-limbic responses to images of high-calorie foods. International Journal of Eating Disorders, 43(1), 6–13. [https://doi.org/10.1002/eat.20658](https://doi.org/10.1002/eat.20658)
- Renshaw, P. F., Daniels, S., Lundahl, L. H., Rogers, V., & Lukas, S. E. (1999). Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: A preliminary report. Psychopharmacology, 142(2), 132–138. [https://doi.org/10.1007/s002130050871](https://doi.org/10.1007/s002130050871)

## See also

- [Responsible use](https://psychonautwiki.org/wiki/Responsible_use)
- [Alpha-GPC](https://psychonautwiki.org/wiki/Alpha-GPC)
- [Choline](https://psychonautwiki.org/wiki/Choline)
- [Nootropic](https://psychonautwiki.org/wiki/Nootropic)

## External links

- [Citocholine (Wikipedia)](https://en.wikipedia.org/wiki/Citicoline)
- [Citocholine (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=11372)
- [Citocholine (Examine)](https://examine.com/supplements/cdp-choline/)

## References
1. ↑ Zeisel, S. H., Costa, K.-A. da (November 2009).["Choline: an essential nutrient for public health"](https://academic.oup.com/nutritionreviews/article-lookup/doi/10.1111/j.1753-4887.2009.00246.x).*Nutrition Reviews*.**67**(11): 615–623.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1111/j.1753-4887.2009.00246.x](//doi.org/10.1111%2Fj.1753-4887.2009.00246.x).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0029-6643](//www.worldcat.org/issn/0029-6643).
2. ↑ Fioravanti, M.; Buckley, A. E. (2006).["Citicoline (Cognizin) in the treatment of cognitive impairment"](//www.ncbi.nlm.nih.gov/pmc/articles/PMC2695184).*Clinical Interventions in Aging*.**1**: 247–251.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.2147/ciia.2006.1.3.247](//doi.org/10.2147%2Fciia.2006.1.3.247).[eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN)[1178-1998](//www.worldcat.org/issn/1178-1998).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1176-9092](//www.worldcat.org/issn/1176-9092).[OCLC](http://en.wikipedia.org/wiki/OCLC)[317918656](//www.worldcat.org/oclc/317918656).[PMC](http://en.wikipedia.org/wiki/PubMed_Central)[2695184](//www.ncbi.nlm.nih.gov/pmc/articles/PMC2695184).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[18046877](//www.ncbi.nlm.nih.gov/pubmed/18046877).
3. ↑ Jiang, N., Huang, J., Edwards, L. J., Liu, B., Zhang, Y., Beal, C. D., Evavold, B. D., Zhu, C. (January 2011).["Two-Stage Cooperative T Cell Receptor-Peptide Major Histocompatibility Complex-CD8 Trimolecular Interactions Amplify Antigen Discrimination"](https://linkinghub.elsevier.com/retrieve/pii/S1074761310004966).*Immunity*.**34**(1): 13–23.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.immuni.2010.12.017](//doi.org/10.1016%2Fj.immuni.2010.12.017).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1074-7613](//www.worldcat.org/issn/1074-7613).
4. ↑ 4.0 4.1 Renshaw, P. F., Daniels, S., Lundahl, L. H., Rogers, V., Lukas, S. E. (18 February 1999).["Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report"](http://link.springer.com/10.1007/s002130050871).*Psychopharmacology*.**142**(2): 132–138.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/s002130050871](//doi.org/10.1007%2Fs002130050871).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0033-3158](//www.worldcat.org/issn/0033-3158).
5. ↑ Glier, M. B., Green, T. J., Devlin, A. M. (January 2014).["Methyl nutrients, DNA methylation, and cardiovascular disease"](https://onlinelibrary.wiley.com/doi/10.1002/mnfr.201200636).*Molecular Nutrition & Food Research*.**58**(1): 172–182.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/mnfr.201200636](//doi.org/10.1002%2Fmnfr.201200636).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1613-4125](//www.worldcat.org/issn/1613-4125).
6. ↑ Killgore, W. D. S., Ross, A. J., Kamiya, T., Kawada, Y., Renshaw, P. F., Yurgelun-Todd, D. A. (2009).["Citicoline affects appetite and cortico-limbic responses to images of high-calorie foods"](https://onlinelibrary.wiley.com/doi/10.1002/eat.20658).*International Journal of Eating Disorders*: NA–NA.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/eat.20658](//doi.org/10.1002%2Feat.20658).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0276-3478](//www.worldcat.org/issn/0276-3478).
7. ↑ Hamurtekin, E., Sibel Gurun, M. (October 2006).["The antinociceptive effects of centrally administered CDP-choline on acute pain models in rats: The involvement of cholinergic system"](https://linkinghub.elsevier.com/retrieve/pii/S0006899306023481).*Brain Research*.**1117**(1): 92–100.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.brainres.2006.07.118](//doi.org/10.1016%2Fj.brainres.2006.07.118).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0006-8993](//www.worldcat.org/issn/0006-8993).
8. ↑ Bagdas, D., Sonat, F. A., Hamurtekin, E., Sonal, S., Gurun, M. S. (September 2011).["The antihyperalgesic effect of cytidine-5′-diphosphate-choline in neuropathic and inflammatory pain models"](https://journals.lww.com/00008877-201109000-00026).*Behavioural Pharmacology*.**22**(5 and 6): 589–598.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1097/FBP.0b013e32834a1efb](//doi.org/10.1097%2FFBP.0b013e32834a1efb).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0955-8810](//www.worldcat.org/issn/0955-8810).
9. ↑ Kashyap, A. S. (1 May 2000).["Fish odour syndrome"](https://pmj.bmj.com/lookup/doi/10.1136/pmj.76.895.318a).*Postgraduate Medical Journal*.**76**(895): 318a–3318.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1136/pmj.76.895.318a](//doi.org/10.1136%2Fpmj.76.895.318a).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0032-5473](//www.worldcat.org/issn/0032-5473).
10. ↑ Parisi, V., Coppola, G., Centofanti, M., Oddone, F., Maria Angrisani, A., Ziccardi, L., Ricci, B., Quaranta, L., Manni, G. (2008). "Progress in Brain Research".[Evidence of the neuroprotective role of citicoline in glaucoma patients](https://linkinghub.elsevier.com/retrieve/pii/S0079612308011370).**173**. Elsevier. pp. 541–554.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/S0079-6123(08)01137-0](//doi.org/10.1016%2FS0079-6123%2808%2901137-0).[ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number)[9780444532565](http://en.wikipedia.org/wiki/Special:BookSources/9780444532565).
11. ↑ McGlade, E., Locatelli, A., Hardy, J., Kamiya, T., Morita, M., Morishita, K., Sugimura, Y., Yurgelun-Todd, D. (2012).["Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women"](http://www.scirp.org/journal/doi.aspx?DOI=10.4236/fns.2012.36103).*Food and Nutrition Sciences*.**03**(06): 769–773.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.4236/fns.2012.36103](//doi.org/10.4236%2Ffns.2012.36103).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[2157-944X](//www.worldcat.org/issn/2157-944X).
12. ↑ Tayebati, S. K., Tomassoni, D., Nwankwo, I. E., Di Stefano, A., Sozio, P., Cerasa, L. S., Amenta, F. (1 February 2013). "Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain".*CNS & neurological disorders drug targets*.**12**(1): 94–103.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.2174/1871527311312010015](//doi.org/10.2174%2F1871527311312010015).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1996-3181](//www.worldcat.org/issn/1996-3181).
13. ↑ Trabucchi, M., Govoni, S., Battaini, F. (April 1986). "Changes in the interaction between CNS cholinergic and dopaminergic neurons induced by L-alpha-glycerylphosphorylcholine, a cholinomimetic drug".*Il Farmaco; Edizione Scientifica*.**41**(4): 325–334.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0430-0920](//www.worldcat.org/issn/0430-0920).NewPP limit report Cached time: 20251218075250 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.033 seconds CPU time usage: 0.307 seconds Real time usage: 0.650 seconds Preprocessor visited node count: 1495/1000000 Post‐expand include size: 89282/2097152 bytes Template argument size: 6768/2097152 bytes Highest expansion depth: 12/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 22619/5000000 bytes Lua time usage: 0.260/7 seconds Lua virtual size: 8.04 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 11Transclusion expansion time report (%,ms,calls,template) 100.00% 538.194 1 -total 52.94% 284.924 12 Template:Cite_journal 21.13% 113.731 2 Template:Citation_needed 12.33% 66.335 1 Template:Fix 11.44% 61.561 1 Template:SubstanceBox/Citicoline 11.36% 61.117 2 Template:Category_handler 10.67% 57.433 1 Template:SubstanceBox 5.21% 28.020 1 Template:Effects/base 4.51% 24.280 1 Template:Effect_list 4.42% 23.815 1 Template:Cite_book`,
  "wikipedia": `# Citicoline
*Source: https://en.wikipedia.org/wiki/Citicoline*

Citicoline (INN), also known as cytidine diphosphate-choline (CDP-choline) or cytidine 5'-diphosphocholine is an intermediate in the generation of phosphatidylcholine from choline, a common biochemical process in cell membranes. Citicoline is naturally occurring in the cells of human and animal tissue, in particular the organs.

## Use as a dietary supplement

Citicoline is available as a supplement in over 70 countries under a variety of brand names: CereBleu, Cebroton, Ceraxon, Cidilin, Citifar, Cognizin, Difosfocin, Hipercol, NeurAxon, Nicholin, Sinkron, Somazina, Synapsine, Startonyl, Trausan, Xerenoos, etc. When taken as a supplement, citicoline is hydrolyzed into choline and cytidine in the intestine. Once these cross the blood–brain barrier, they are 
reformed into citicoline by the rate-limiting enzyme in phosphatidylcholine synthesis, CTP-phosphocholine cytidylyltransferase.

## Research

### Ischemic stroke

Some preliminary research suggested that citicoline may reduce the rates of death and disability following an ischemic stroke.
However, the largest citicoline clinical trial to date (a randomised, placebo-controlled, sequential trial of 2,298 patients with moderate-to-severe acute ischaemic stroke in Europe), found no benefit of administering citicoline on survival or recovery from stroke. A meta-analysis of seven trials reported no statistically significant benefit for long-term survival or recovery.

### Vision

The effect of citicoline on visual function has been studied in patients with glaucoma, with possible positive effect for protecting vision.

## Mechanism of action

### Neuroprotective effects

Citicoline may have neuroprotective effects due to its preservation of cardiolipin and sphingomyelin, preservation of arachidonic acid content of phosphatidylcholine and phosphatidylethanolamine, partial restoration of phosphatidylcholine levels, and stimulation of glutathione synthesis and glutathione reductase activity. Citicoline's effects may also be explained by the reduction of phospholipase A2 activity. 
Citicoline increases phosphatidylcholine synthesis. The mechanism for this may be:

By converting 1, 2-diacylglycerol into phosphatidylcholine
Stimulating the synthesis of SAMe, which aids in membrane stabilization and reduces levels of arachidonic acid. This is especially important after an ischemia when arachidonic acid levels are elevated.

### Neuronal membrane

The brain preferentially uses  choline to synthesize acetylcholine. This limits the amount of choline available to synthesize phosphatidylcholine. When the availability of choline is low or the need for acetylcholine increases, phospholipids containing choline can be catabolized from neuronal membranes. These phospholipids include sphingomyelin and phosphatidylcholine. Supplementation with citicoline can increase the amount of choline available for acetylcholine synthesis and aid in rebuilding membrane phospholipid stores after depletion. 
Citicoline decreases phospholipase stimulation. This can lower levels of hydroxyl radicals produced after an ischemia and prevent cardiolipin from being catabolized by phospholipase A2. It can also work to restore cardiolipin levels in the inner mitochondrial membrane.

### Cell signalling

Citicoline may enhance cellular communication by increasing levels of neurotransmitters. The choline component of citicoline is used to create acetylcholine, which is a neurotransmitter in the human brain. Clinical trials have found that citicoline supplementation might improve focus and attention.

### Glutamate transport

Citicoline lowers increased glutamate concentrations and raises decreased ATP concentrations induced by ischemia. Citicoline also increases glutamate uptake by increasing expression of EAAT2, a glutamate transporter, in vitro in rat astrocytes. It is suggested that the neuroprotective effects of citicoline after a stroke are due in part to citicoline's ability to decrease levels of glutamate in the brain. This is in part due to an indirect decrease in the extrasynaptic NMDA-TRMP4 death signaling pathway. It's important to also note it is only the extrasynaptic NMDA receptors responsible for excitotoxicity.

## Pharmacokinetics

Citicoline is water-soluble, with more than 90% oral bioavailability. Plasma levels of citicholine peak one hour after oral ingestion, and a majority of the citicoline is excreted as CO2 in respiration with the remaining citicoline being excreted through urine. The pharmacokinetic profile of citicholine cannot be described by a single smooth exponential decrease over time. However, the elimination half-life for citicholine has been reported as approximately 50 hours for citicholine removed via respiration and approximately 70 hours for citicholine removed via urine. Plasma levels of choline peak about four hours after ingestion.

### Side effects

Citicoline has a very low toxicity profile in animals and humans. Clinically, doses of 2000 mg per day have been observed and approved. Minor transient adverse effects are rare and most commonly include stomach pain and diarrhea. A 2020 study reported that concerns had emerged that chronic citicoline use may have adverse psychiatric effects, however, the study's meta-analysis of the relevant literature did not support this hypothesis. Citicoline may exacerbate psychotic episodes or interact with antipsychotic medication.

## Synthesis

### In vivo

Phosphatidylcholine is a major phospholipid in eukaryotic cell membranes. Close regulation of its biosynthesis, degradation, and distribution is essential to proper cell function. Phosphatidylcholine is synthesized in vivo by two pathways

The Kennedy pathway, which includes the transformation of choline to citicoline, by way of phosphorylcholine, produces phosphatidylcholine when condensed with diacylglycerol.
Phosphatidylcholine can also be produced by the methylation pathway, where phosphatidylethanolamine is sequentially methylated.
`,
};
